Epysqli safety and efficacy similar in Asian, non-Asian PNH patients
Epysqli (SB12), a biosimilar of Soliris (eculizumab), is comparable in safety and efficacy for Asian and non-Asian patients with paroxysmal nocturnal hemoglobinuria (PNH). That’s according to a post-hoc analysis of the pivotal Phase 3 SB12 study (NCT04058158), the findings of which supported Epysqli’s approval in the U.S.